The global obesity epidemic continues to surge, leading to an unprecedented demand for effective treatments and numerous clinical trials. As a result, the clinical trial landscape is rapidly expanding, with numerous companies conducting a wide array of obesity-related studies. Among these, GLP-1 receptor agonists have emerged as a leading therapeutic option, prompting a significant increase …
The prevalence of duplicate participants in clinical trials poses significant risks, compromising the integrity of data and the safety of the patients involved. To delve into this matter, we spoke with Kerri Weingard, a seasoned veteran in the field and the co-founder of Verified Clinical Trials (VCT), who brings a wealth of knowledge and experience. In this …
January 30, 2025 07:07 ET | Source: Velocity Clinical Research, Inc.Follow DURHAM, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) — Velocity Clinical Research, the leading multi-specialty clinical research organization, has partnered with Verified Clinical Trials (VCT) to set a new benchmark for patient safety and data quality in clinical trials through a new technological implementation at Velocity’s 80+ …
In the dynamic world of clinical research, ensuring data integrity and participant safety is paramount. One of the most significant challenges faced by clinical trials today is the issue of duplicate subjects in clinical trials—participants who enroll in multiple studies simultaneously or consecutively without proper washout periods. This practice can jeopardize study outcomes, compromise data …
We’re excited to announce that Verified Clinical Trials (VCT) will be exhibiting and hosting a special panel discussion focused on the growing challenges of duplicate and professional subjects in vaccine clinical trials. Vaccine clinical trials present a unique set of challenges, particularly when it comes to subject verification. Unlike many other clinical studies, vaccine trials …
Clinical research patients are compensated for their participation in clinical trials. In some therapeutic areas and types of clinical trials, the compensation for enrolling in one or more clinical trials or at multiple research sites is enough to influence patients to join more than one contemporaneously and expose themselves to multiple investigational products or multiple …
Duplicate subjects, or what is known as professional research subjects, exist in most clinical trials to varying degrees. CNS clinical trials are especially prone to duplicate subjects or over enrollment in clinical tials. The issue exists from phase 1 healthy volunteer studies to multiple phase 2/3 clinical trials across many therapeutic indications. Use of global …
Professional research subjects cause issues with placebo rates, data quality and safety. The issue is more common than most would think. Upwards of 10% of research subjects will attempt to enroll in more than one clinical trial concurrently or before a safe and mandatory wash out period has occurred. Without a tool like Verified Clinical …
Verified Clinical Trials (VCT) presented a poster at the ASCP meeting in Phoenix May 2019, detailing travel habits and distances specifically in CNS clinical trials. Bottom line: In many instances, research subjects travel large distances to become duplicate subjects in CNS clinical trials. A research subject database is needed to prevent duplicate subjects and many …
Without a “tool” such as the Verified Clinical Trials (VCT) global research subjects database registry, detecting duplicate subjects and protocol violations based upon prior study history or prior study drug (IP) exposure is impossible. VCT proactively detects these issues at the time of screening before costly screening procedures occur. The protections continue the entire duration …
